Progressive Multifocal Leukoencephalopathy Treatment Market Report 2026

Progressive Multifocal Leukoencephalopathy Treatment Market Overview

• Progressive Multifocal Leukoencephalopathy Treatment market size has reached to $1.6 billion in 2025 • Expected to grow to $2.61 billion in 2030 at a compound annual growth rate (CAGR) of 10.5% • Growth Driver: Impact Of HIV Infection Prevalence On The Progressive Multifocal Leukoencephalopathy (PML) Market • North America was the largest region in 2025.

What Is Covered Under Progressive Multifocal Leukoencephalopathy Treatment Market?

Progressive multifocal leukoencephalopathy is a severe and rare viral brain infection that primarily affects individuals with weakened immune systems. Its treatment is used to manage symptoms, slow down the progression of the disease, and prevent complications. There is no known treatment for PML and the virus's harm cannot be reversed. The main types of treatments for progressive multifocal leukoencephalopathy are anti-retroviral therapy, antiviral or anti-John Cunningham virus (JCV), and others. Antiretroviral therapy refers to the combination of medications used to treat infections caused by retroviruses, particularly the human immunodeficiency virus. These are used to indicate HIV or AIDS, organ transplantation, multiple sclerosis, and hematologic malignancies. These can be administered through various routes, including oral, parenteral, and others, and are used by several end-users, such as hospitals, homecare, specialty centers, and others.

What Is The Progressive Multifocal Leukoencephalopathy Treatment Market Growth Forecast?

The progressive multifocal leukoencephalopathy treatment market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing research into targeted antiviral therapies, rising demand for early diagnostic tools, expansion of precision medicine approaches, growing focus on immune system modulation, increasing clinical collaborations for rare viral diseases. Major trends in the forecast period include increasing focus on immunomodulatory treatment strategies, rising use of advanced neuroimaging diagnostics, growing emphasis on early detection in immunocompromised patients, expansion of supportive and symptom management therapies, enhanced integration of multidisciplinary care teams.

Global Progressive Multifocal Leukoencephalopathy Treatment Market Segmentation

1) By Treatment: Anti-retroviral Therapy, Antiviral Or Anti-John Cunningham Virus (JCV), Other Symptomatic 2) By Indication: HIV Or AIDS, Organ Transplantation, Multiple Sclerosis, Hematologic Malignancies 3) By Route of Administration: Oral, Parenteral, Other Routes Of Administration 4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users Subsegments: 1) By Anti-retroviral Therapy: NRTIs (Nucleoside Reverse Transcriptase Inhibitors), NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors), PIs (Protease Inhibitors), Integrase Inhibitors 2) By Antiviral Or Anti-John Cunningham Virus (JCV): Natalizumab, Fumaric Acid Esters, Other JCV-targeted Therapies 3) By Other Symptomatic Treatments: Corticosteroids, Immunomodulators, Supportive Care, Symptomatic Relief Medications

What Are The Drivers Of The Progressive Multifocal Leukoencephalopathy Treatment Market?

The growing prevalence of human immunodeficiency virus (HIV) infection is expected to propel the growth of the progressive multifocal leukoencephalopathy market going forward. HIV is a retrovirus that attacks the immune system, specifically targeting CD4 cells (also known as T cells), which play a crucial role in helping the body fight infections. Most patients with HIV infection develop PML due to a poor immunological condition, indicated by a low CD4 cell count (200/L), the single most significant cause of PML cases worldwide. When a severe HIV-related immune deficit arises, the latent JCV archetype strain in the brain may increase, leading to brain white matter lesions and PML. For instance, in July 2025, according to the according to the World Health Organization, a Switzerland-based international health organization, By the end of 2024, approximately 40.8 million people were living with HIV globally, including 1.4 million children aged 0–14 years [1.1–1.8 million] and 39.4 million adults aged 15 years and older [35.7–44.0 million]. Therefore, the growing prevalence of human immunodeficiency virus (HIV) infection is driving the growth of the progressive multifocal leukoencephalopathy market. The increasing prevalence of neurological disorders is expected to propel the growth of the progressive multifocal leukoencephalopathy market. Neurological disorders are diseases that affect the central and peripheral nervous systems, including the brain, spinal cord, cranial and peripheral nerves, autonomic nervous system, nerve roots, neuromuscular junction, and muscles. The increasing prevalence of neurological disorders is due to the aging population, genetic factors, and infectious diseases. Progressive Multifocal Leukoencephalopathy (PML) treatment helps address the increasing prevalence of neurological disorders by providing targeted therapy for PML, a severe demyelinating brain disease, thereby reducing neurological complications and improving patient outcomes in immunocompromised populations. For instance, in October 2023, according to the World Federation of Neurology, a UK-based association of national neurological societies, more than 40% of the global population currently experiences some form of neurological condition, and this burden is expected to nearly double by 2050. Therefore, the increasing prevalence of neurological disorders is driving the progressive multifocal leukoencephalopathy market. The rising research and development activities are expected to propel the growth of the progressive multifocal leukoencephalopathy treatment market going forward. Rising research and development (R&D) activities refer to the increasing efforts and investments directed toward scientific investigation, experimentation, and innovation in various fields. Research and development activities are critically important for the treatment and management of progressive multifocal leukoencephalopathy (PML) for the development of improved therapies, earlier diagnosis, and better management of the disease. For instance, in February 2025, according to the National Center for Science and Engineering Statistics (NCSES), a US-based government statistical agency, U.S. research and development expenditures rose from $892 billion in 2022 to $940 billion in 2023, reflecting an increase of $48 billion. Therefore, rising research and development activities are driving the growth of the progressive multifocal leukoencephalopathy treatment industry.

Key Players In The Global Progressive Multifocal Leukoencephalopathy Treatment Market

Major companies operating in the progressive multifocal leukoencephalopathy treatment market are Pfizer Inc, Johnson And Johnson, Roche Holding AG, Merck And Co Inc, AbbVie Inc, Novartis AG, Bristol Myers Squibb Company, Sanofi SA, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Gilead Sciences Inc, Viatris Inc, Teva Pharmaceutical Industries Ltd, Biogen Inc, Otsuka Pharmaceutical Co Ltd, Jazz Pharmaceuticals plc, Ipsen Pharma, Apotex Inc, Alkermes plc, Genentech Inc, Neurimmune AG, NeoImmuneTech, Inhibikase Therapeutics Inc, Bayer AG

Regional Outlook

North America was the largest region in the progressive multifocal leukoencephalopathy treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Progressive Multifocal Leukoencephalopathy Treatment Market?

The progressive multifocal leukoencephalopathy treatment market consists of revenues earned by entities by providing plasmapheresis, immune reconstitution therapy, physical therapy, supportive care, and consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. The progressive multifocal leukoencephalopathy treatment market also includes sales of cidofovir, Brin cidofovir, and mefloquine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Progressive Multifocal Leukoencephalopathy Treatment Market Report 2026?

The progressive multifocal leukoencephalopathy treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the progressive multifocal leukoencephalopathy treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.